PRQR ProQR Therapeutics N.V.

-0.54  -5%
Previous Close 11.88
Open 11.82
Price To Book 4.2
Market Cap 440819094
Shares 38,872,936
Volume 166,134
Short Ratio
Av. Daily Volume 237,009

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 pivotal trial to commence 1H 2019 with interim data YE 2020.
Sepofarsen (QR-110 ) ILLUMINATE
Leber's Congenital Amaurosis (LCA) - Genetic blindness
Phase 1b top-line data released September 25, 2017. FEV levels not significant across four doses. One of four doses showed significance in subgroup.
Cystic Fibrosis
Phase 1/2 interim analysis announced March 26, 2019. Future development to be conducted by Wings Therapeutics.
Epidermolysis bullosa
Phase 1/2 trial to be initiated 2019.
autosomal dominant retinitis pigmentosa (adRP)
Phase 1/2 interim data due mid-2019.
Usher Syndrome Type 2

Latest News

  1. ProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board
  2. ProQR Announces Annual Meeting of Shareholders
  3. ProQR Initiates Dosing in Phase II/III Eye Disorder Study
  4. ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10
  5. ProQR to Present at the H.C. Wainwright Global Life Sciences Conference
  6. ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership
  7. ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
  8. ProQR to Present at Cowen Health Care Conference
  9. Medicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus
  10. ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
  11. Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer
  12. Vertex's Kalydeco Wins Health Canada Nod to Treat CF in Kids
  13. ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day
  14. Should You Worry About ProQR Therapeutics N.V.’s (NASDAQ:PRQR) CEO Salary Level?
  15. ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10
  16. Company News For Jan 3, 2019
  17. ProQR to Host R&D Day in New York on January 29
  18. Best Sector of 2018 and its Hit ETFs & Stocks
  19. ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2
  20. ProQR Therapeutics Added to NASDAQ Biotechnology Index